Literature DB >> 11269569

Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose.

I Bekersky1, D Dressler, Q Mekki.   

Abstract

Tacrolimus (FK506, Prograf) is marketed for the prophylaxis of organ rejection following allogenic liver or kidney transplantation. This study investigated the effect of timing of a standardized breakfast meal on both the rate and extent of tacrolimus absorption following a single 5 mg oral dose. The protocol used a randomized, open-label, four-period, four-treatment, four-sequence crossover design in 16 healthy, nonsmoking, drug-free male subjects between the ages of 22 and 45 years who were within 15% of their ideal body weight. The four treatments were the following: (A) fasting for 10 hours, (B) ingestion 1 hour before breakfast, (C) ingestion immediately following consumption of the breakfast, and (D) ingestion 1.5 hours after beginning consumption of the breakfast. The breakfast, which was consumed over 15 minutes, contained 848 kcal, with 30%, 16%, and 54% of calories derived from fat, protein, and carbohydrate, respectively. Tacrolimus absorption in the fasting state provided the greatest relative bioavailability (p < 0.05 compared with all other three treatments). AUC(0-infinity)) averaged 312, 276, 205, and 203 ng x h/mL for treatments A, B, C and D, respectively. In contradistinction to taking the drug 1 hour prior to a meal, which had a relatively minor impact on the relative extent of absorption (approximately 12%) compared to the fasting state, ingestion of tacrolimus immediately after a meal (treatment C) or 1.5 hours subsequent to a meal (treatment D) had a more pronounced influence. Mean AUC(0-infinity) ratios (fasting to either postmeal treatments) were approximately 1.5, indicating that absorption extent was considerably reduced by ingesting tacrolimus capsules immediately after eating or 1.5 hours thereafter. Absorption was also prolonged following drug ingestion after a meal, as indicated by a mean tmax value in the fasting state of 1.84 hours, relative to 3.41 hours (immediately aftermeal, p = 0.0035) and 3.22 hours (1.5 hours postmeal, p = 0.0094). The only discernable difference in parameters between treatments C and D was with Cmax, with values of 7.19 and 9.04 ng/mL, respectively, but was not statistically significantly different (p = 0.231). Based on these results and those from a prior study, it is recommended that under therapeutic conditions, oral tacrolimus be administered in a consistent manner, both with respect to the type of meal as well as timing of ingestion relative to consumption of the meal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11269569     DOI: 10.1177/00912700122010104

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  22 in total

1.  Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients.

Authors:  Katherine A Barraclough; Nicole M Isbel; Carl M Kirkpatrick; Katie J Lee; Paul J Taylor; David W Johnson; Scott B Campbell; Diana R Leary; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.

Authors:  Chen-Yan Zhao; Zheng Jiao; Jun-Jun Mao; Xiao-Yan Qiu
Journal:  Br J Clin Pharmacol       Date:  2016-02-26       Impact factor: 4.335

3.  Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers.

Authors:  Hua-Wen Xin; Xiao-Chun Wu; Qing Li; Ai-Rong Yu; Min Zhu; Yang Shen; Dan Su; Lei Xiong
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

4.  Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.

Authors:  T Vanhove; P Annaert; D Lambrechts; D R J Kuypers
Journal:  Pharmacogenomics J       Date:  2016-07-05       Impact factor: 3.550

Review 5.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.

Authors:  Shigeru Satoh; Hideaki Kagaya; Mitsuru Saito; Takamitsu Inoue; Masatomo Miura; Kazuyuki Inoue; Kazuyuki Numakura; Norihiko Tsuchiya; Hitoshi Tada; Toshio Suzuki; Tomonori Habuchi
Journal:  Br J Clin Pharmacol       Date:  2008-04-22       Impact factor: 4.335

8.  The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients.

Authors:  Giovanni Montini; Francesca Ujka; Cristina Varagnolo; Luciana Ghio; Fabrizio Ginevri; Luisa Murer; Basile S Thafam; Carla Carasi; Graziella Zacchello; Mario Plebani
Journal:  Pediatr Nephrol       Date:  2006-03-21       Impact factor: 3.714

9.  Excess fluid distribution affects tacrolimus absorption in peritoneal dialysis patients.

Authors:  Tadashi Sofue; Masashi Inui; Hideyasu Kiyomoto; Kumiko Moriwaki; Taiga Hara; Kazunori Yamaguchi; Noriyasu Fukuoka; Kazuko Banno; Akira Nishiyama; Yoshiyuki Kakehi; Masakazu Kohno
Journal:  Clin Exp Nephrol       Date:  2012-12-27       Impact factor: 2.801

Review 10.  Tacrolimus: a further update of its use in the management of organ transplantation.

Authors:  Lesley J Scott; Kate McKeage; Susan J Keam; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.